Does Medical Cannabis Reduce Opioid Use in Adults With Pain

Completed

• Conditions: Opioid Use; Chronic Pain; Marijuana

• Registration Number: NCT04308148
• Lead Sponsor: Albert Einstein College of Medicine

Brief Summary

The study will examine how medical cannabis use affects opioid analgesic use. This landmark study will be among the first to examine the effect of medical cannabis with different THC/CBD (Tetrahydrocannibinol/Cannabidiol) content on opioid use as well as adverse events.

Detailed Description

This study will examine how medical cannabis use affects opioid analgesic use, with particular attention to THC/CBD (Tetrahydrocannibinol/Cannabidiol) content and adverse events. We will enroll adults with (a) severe or chronic neuropathic or joint pain, (b) prescribed opioid analgesic use, (c) active certification for medical cannabis, and (d) intends to have soft gel capsule products dispensed at Vireo (medical cannabis dispensary) (including a high THC:low CBD product, an equal THC:CBD (Tetrahydrocannibinol:Cannabidiol) product, and a low THC:high CBD product). Over the 14 weeks, data sources will include questionnaires; medical, pharmacy, and Prescription Monitoring Program (PMP) records; and urine samples. The primary independent variable will be type of soft gel capsule product, and the primary outcome will be cumulative opioid analgesic dose.

Study Timeline

• Study First Submitted: 2020-03-12
• Study First Submitted QC: 2020-03-12
• Study First Posted: 2020-03-13
• Study Start: 2020-10-06
• Status Verified: 2024-03
• Primary Completion: 2024-03-13
• Study Completion: 2024-03-13
• Last Update Submitted: 2024-03-21
• Last Update Posted: 2024-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 217

Inclusion Criteria

• At least 18 years of age
• English or Spanish fluency
• Actively certified for medical cannabis
• Intends to have a soft-gel capsule product dispensed at Vireo
• Medical cannabis qualifying conditions or complications of "chronic or severe pain" or "pain that degrades health and functional capability as an alternative to opioid use or substance use disorder"
• Joint or neuropathic pain
• Current severe pain
• Dispensed opioid analgesics within the last 60 days

To maintain the integrity of the study, we do not disclose all inclusion criteria to potential participants.

Read More

Exclusion Criteria

• Inability to provide informed consent
• Inability to complete study visits over 14 weeks
• Terminal illness
• Current or prior psychotic disorder
• Buprenorphine or methadone treatment for opioid use disorder within the past year
• Allergies to tapioca or coconut
• Currently pregnant, planning to become pregnant within the next 3 months, or breastfeeding
• Condition that is considered by a pharmacist or medical provider to be a contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific drug-use interaction)

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Opioid analgesic use	Opioid analgesic use will be weekly cumulative dose of opioid analgesics over 14 weeks.	The primary outcome will be opioid analgesic use.

Secondary Outcome Measures

Name	Time	Method
Adverse events	Adverse events will be over 14 weeks	(e.g. Cannabis use disorder, illicit drug use, diversion of medical cannabis, accidents and injuries)

Trial Locations

Locations (1)

Montefiore Health System; 🇺🇸 Bronx, New York, United States